ClinicalTrials.gov
ClinicalTrials.gov Menu

LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study (LFIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00510458
Recruitment Status : Completed
First Posted : August 2, 2007
Results First Posted : March 12, 2018
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
Stryker Orthopaedics

Brief Summary:
Total hip replacement surgery is considered to be a very successful surgical procedure for the treatment of degenerative joint disease. The purpose of the study is to evaluate a large size (36mm, 40mm or 44mm) femoral (hip) head called the LFIT™ Anatomic CoCr Femoral Head (Low Friction Ion Treatment). The large size femoral heads will be used with the Trident® X3® polyethylene (plastic) inserts and will be compared with a historical control. Study Hypothesis: The linear wear rate for hips implanted with the LFIT™ Anatomic CoCr Femoral Head is no worse than 0.08 mm wear per year at 5 years post-surgery.

Condition or disease Intervention/treatment Phase
Arthroplasty, Replacement, Hip Device: LFIT™ Femoral Heads With X3® Insert Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts
Study Start Date : April 2007
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hip Replacement

Arm Intervention/treatment
LFIT™Femoral Heads With X3® Insert
LFIT™ Femoral Heads With X3® Insert
Device: LFIT™ Femoral Heads With X3® Insert
LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement




Primary Outcome Measures :
  1. Linear Wear Rate [ Time Frame: 5 Years Post-Surgery ]

    Linear wear rate is defined as the annual rate of removal of the polyethylene from the X3 polyethylene insert mated with LFIT™ Anatomic CoCr Femoral Heads determined by comparing digitized images of serial radiographs obtained over the follow-up period.



Secondary Outcome Measures :
  1. Change in Harris Hip Score (HHS) From Pre-operative to Post-operative Visits [ Time Frame: preoperative, 1, 3, and 5 years ]

    The change in HHS is reported by comparing the mean preoperative, 1, 3, and 5 year scores. The HHS assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor.

    90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor


  2. Change in Harris Hip Score (HHS) Pain Score From Pre-operative to Post-operative Visits [ Time Frame: preop, 1, 3, and 5 Years ]

    This subscore of the overall HHS provides the patient with 6 possible answers to choose from ranging from, no pain/ignores it, to totally disabled/crippled/pain in bed/bedridden. A maximum of 44 points is possible for this subscore indicating no pain/ignores it.

    Pain:

    1. None or ignores it = 44 points
    2. Slight, occasional, no compromise in activities = 40 points
    3. Mild pain, no effect on average activities, rarely moderate pain with unusual activity, may take aspirin = 30 points
    4. Moderate pain, tolerable but makes concessions to pain. Some limitation of ordinary activity or work. May require occasional pain medicine stronger than aspirin = 20 points
    5. Marked pain, serious limitation of activities = 10 points
    6. Totally disabled, crippled, pain in bed, bedridden = 0 points

  3. Change in Harris Hip Score (HHS) Range of Motion (ROM) Score From Pre-operative to Post-operative Visits. [ Time Frame: preoperative, 1, 3, and 5 Years ]

    This subscore of the overall HHS includes the total points awarded for five different ranges of motion (flexion, abduction, external rotation, internal rotation, adduction). Subscore range is minimum of 0 to maximum of 5 points; the higher the value, the better the outcome.

    Flexion:

    0-45 degrees x 1.0 index value = max 45 points

    45-90 degrees x 0.6 index = max 27 points

    90-110 degrees x 0.3 index = max 6 points

    110-130 degrees = max 0 points

    Abduction:

    0-15 degrees x 0.8 index = max 12 points

    15-20 degrees x 0.3 index = max 1.5 points

    20-45 degrees x 0 index = max 0 points

    External Rotation in extension:

    0-15 degrees x 0.4 index = max 6 points

    Over 15 degrees = max 0 points

    Internal Rotation in extension:

    Any = max 0 points

    Adduction:

    0-15 degrees x 0.2 index = max 3 points

    Over 15 degrees - max 0 points

    To determine the over-all rating for range of motion, multiply the sum of the index values x 0.05.


  4. Change in SF-12 Health Survey Score (Physical and Mental) From Pre-operative to Post-operative Intervals. [ Time Frame: preop, 1, 3, and 5 Years ]
    The change in SF-12 is reported by comparing the mean preoperative, 1, 3, and 5 year scores. The SF-12 Health Survey is a 12 item patient completed questionnaire to measure general health and well-being. It includes a physical component score and mental status component score; each ranging from 0-100. Low values represent a poor health state and high values represent a good health state.

  5. Change in Lower Extremity Activity Scale (LEAS) From Pre-operative to Post-operative [ Time Frame: preoperative, 1, 3, and 5 Years ]
    The change in LEAS is reported by comparing the mean pre-operative, 1,3,and 5 year scores. The LEAS completed by the participant to assess activity level. Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level.

  6. Number of Hips That Dislocated [ Time Frame: 3 and 5 years ]
    The number of hips that experienced a hip dislocation.

  7. Number of Hips Evaluated as Radiographically Unstable [ Time Frame: 1, 3, 5 years ]

    Radiographic instability is defined as having any of the following findings on x-ray:

    • Radiographic indication of progressive radiolucent lines ≥ 2 mm in thickness around the entire acetabular component
    • Radiographic indication of migration of ≥ 3 mm or ≥ 5° of the acetabular component
    • Radiographic indication of progressive radiolucent lines ≥ 2 mm thickness around the entire femoral component
    • Radiographic indication of progressive subsidence of the femoral component of ≥ 5 mm.

  8. Percentage of Cases That Did Not Have Any Component Revised [ Time Frame: 5 years ]

    A revision is defined as surgical removal and replacement of the femoral bearing head or femoral stem components, or the acetabular shell or acetabular polyethylene liner.

    The 97.42% estimate is obtained by Kaplan-Meier method.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is candidate for a primary cementless total hip replacement, and a posterolateral surgical approach is planned.
  2. Patient's preoperative templating predicts the use of a Hemispherical Acetabular Shell size 52mm or larger.
  3. Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD). Patient must have diagnosis of osteoarthritis (OA), traumatic arthritis (TA), avascular necrosis (AVN), slipped capital epiphysis, pelvic fracture, femoral fracture, failed fracture fixation, or diastrophic variant
  4. Patient is a male or non-pregnant female age 18 years or older at time of enrollment.
  5. Patient has signed an IRB approved, study specific Informed Patient Consent Form.
  6. Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.

Exclusion Criteria:

  1. Patient has an active infection within the affected hip joint.
  2. Patient requires revision surgery of a previously implanted total hip arthroplasty or hip fusion to the affected joint.
  3. Patient has a Body Mass Index (BMI) ≥ 40.
  4. Patient has a neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
  5. Patient is diagnosed with systemic disease or current life threatening illness and is not able to carry on normal activities of daily life (i.e. Paget's disease, renal osteodystrophy, rheumatoid arthritis).
  6. Patient is immunologically suppressed or receiving chronic steroids in excess of 5mg per day.
  7. Patient has a recent history of substance dependency that may result in deviations from the evaluation schedule.
  8. Patient is a prisoner.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510458


Locations
United States, Florida
Cedars Medical Center University of Miami
Miami, Florida, United States, 33136
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, New Jersey
Seaview Orthopedics
Ocean City, New Jersey, United States, 07712
United States, Oregon
The Center: Orthopedic & Neurosurgical Care & Research
Bend, Oregon, United States, 97701
United States, Pennsylvania
Greater Pittsburgh Orthopaedic Associates
Moon, Pennsylvania, United States, 15108
Sponsors and Collaborators
Stryker Orthopaedics
Investigators
Study Chair: James D'Antonio, MD Greater Pittsburgh Orthopaedic Associates
Principal Investigator: Stephen Thomas, M.D. Greater Pittsburgh Orthopaedic Associates
Principal Investigator: Eric Smith, M.D. Tufts University Medical Center
Principal Investigator: Arthur Mark, M.D. Seaview Orthopaedic

Responsible Party: Stryker Orthopaedics
ClinicalTrials.gov Identifier: NCT00510458     History of Changes
Other Study ID Numbers: 63
First Posted: August 2, 2007    Key Record Dates
Results First Posted: March 12, 2018
Last Update Posted: March 12, 2018
Last Verified: January 2018